APA

Coudert B., Asselain B., Campone M., Spielmann M., Machiels J., Pénault-Llorca F., Serin D., Lévy C., Romieu G., Canon J., Orfeuvre H., Piot G., Petit T., Jerusalem G., Audhuy B., Veyret C., Beauduin M., Eymard J., Martin A. & Roché H. (20130207). Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. : The oncologist.

Chicago

Coudert Bruno, Asselain Bernard, Campone Mario, Spielmann Marc, Machiels Jean-Pascal, Pénault-Llorca Frédérique, Serin Daniel, Lévy Christelle, Romieu Gilles, Canon Jean-Luc, Orfeuvre Hubert, Piot Gilles, Petit Thierry, Jerusalem Guy, Audhuy Bruno, Veyret Corinne, Beauduin Marc, Eymard Jean-Christophe, Martin Anne-Laure and Roché Henri. 20130207. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. : The oncologist.

Harvard

Coudert B., Asselain B., Campone M., Spielmann M., Machiels J., Pénault-Llorca F., Serin D., Lévy C., Romieu G., Canon J., Orfeuvre H., Piot G., Petit T., Jerusalem G., Audhuy B., Veyret C., Beauduin M., Eymard J., Martin A. and Roché H. (20130207). Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. : The oncologist.

MLA

Coudert Bruno, Asselain Bernard, Campone Mario, Spielmann Marc, Machiels Jean-Pascal, Pénault-Llorca Frédérique, Serin Daniel, Lévy Christelle, Romieu Gilles, Canon Jean-Luc, Orfeuvre Hubert, Piot Gilles, Petit Thierry, Jerusalem Guy, Audhuy Bruno, Veyret Corinne, Beauduin Marc, Eymard Jean-Christophe, Martin Anne-Laure and Roché Henri. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. : The oncologist. 20130207.